Daily Sepsis Research Analysis
Analyzed 43 papers and selected 3 impactful papers.
Summary
Engineering-based and mechanistic studies dominated today’s top sepsis research. A Nature Communications study introduces a minimal EV scaffold (EN144) enabling IL-6 decoy EVs that improve survival in murine sepsis, while a Science Advances paper identifies Drp1-driven tunneling nanotubes as key conduits for mitochondrial transfer in septic cardiac remodeling. Clinically, a multicenter cluster-RCT shows the early-onset sepsis calculator safely halves empiric antibiotic use in at-risk newborns.
Research Themes
- Engineered extracellular vesicles and cytokine decoy strategies for sepsis
- Nanoscale intercellular communication and mitochondrial transfer in septic heart
- Implementation science for neonatal early-onset sepsis antibiotic stewardship
Selected Articles
1. Extracellular vesicle engineering using a small scaffold protein.
This study identifies ENPP1 as a superior EV scaffold and introduces a minimal 144-aa variant (EN144) that efficiently loads cargo and displays targeting moieties. EN144-gp130 decoy EVs block IL-6 trans-signaling, reduce inflammation, and improve survival in murine sepsis, highlighting a broadly applicable platform for inflammatory disease therapeutics.
Impact: Provides a minimal, high-performance EV scaffold and demonstrates survival benefit in sepsis by targeting IL-6 trans-signaling. This establishes a versatile therapeutic platform with clear translational potential.
Clinical Implications: Although preclinical, EN144-engineered decoy EVs suggest a path to targeted cytokine neutralization in sepsis and other inflammatory conditions. Future translation could enable precision anti-inflammatory therapy with improved tissue targeting and reduced off-target effects.
Key Findings
- Mass spectrometry-based proteomics identified ENPP1 as a superior EV scaffold; a truncated 144-aa variant (EN144) efficiently loads diverse cargos and outperforms conventional scaffolds.
- EN144 fused to the IL-6 decoy receptor (gp130) generates engineered EVs that potently inhibit IL-6 trans-signaling.
- In mouse sepsis models, EN144-based decoy EVs reduce inflammation and improve survival; cartilage-targeted EVs mitigate osteoarthritis tissue damage.
Methodological Strengths
- Rigorous engineering-validation pipeline combining proteomics discovery with functional in vivo efficacy including survival endpoints.
- Modular platform design demonstrating both cargo loading and targeting across disease models.
Limitations
- Efficacy demonstrated in murine models; no human tissue or clinical data.
- Manufacturing scalability, stability, and regulatory considerations for EV therapeutics not addressed.
Future Directions: Advance to large-animal studies, define pharmacokinetics/biodistribution and dosing, assess safety/toxicology, and develop GMP-compliant manufacturing for first-in-human trials in hyperinflammatory sepsis.
Extracellular vesicles (EVs) are promising drug-delivery vehicles owing to their biocompatibility and low immunogenicity. Genetic engineering of a membrane-bound EV-sorting scaffold protein empowers EVs by installing targeting moieties on the surface and enriching therapeutic cargo in the lumen. However, the choice of scaffold proteins with simple structures and short sequences is limited. Here, we conduct mass spectrometry-based proteomic studies and identify ENPP1 as a superior scaffold protein. Furthermore, we show that a truncated 144-amino acid variant, EN144, efficiently loads diverse therapeutic cargoes and outperforms conventional scaffolds. By fusing EN144 to the IL-6 decoy receptor gp130, we create engineered decoy EVs that potently inhibit inflammatory IL-6 trans-signaling. In mouse models, these EVs reduce inflammation, improve survival in sepsis, and, when targeted to cartilage, alleviate tissue damage in osteoarthritis. Our work establishes EN144 as a minimal, high-performance scaffold for EV engineering and demonstrates its broad therapeutic potential for inflammatory diseases.
2. Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis.
Using CLP sepsis and single-cell RNA-seq, the study shows that Drp1-driven cytoskeletal remodeling orchestrates TNT biogenesis that mediates mitochondrial transfer among cardiac resident cells. Cardiac Drp1 knockout disrupts TNT-mediated exchange, reversing metabolic deterioration and cellular reprogramming during sepsis.
Impact: Reveals a nanoscale organelle communication network driving septic cardiac remodeling and identifies Drp1 as a central regulator, opening a new mechanistic and therapeutic avenue.
Clinical Implications: Targeting Drp1 or TNT biogenesis could become a strategy to prevent or reverse septic cardiomyopathy. Translation will require pharmacologic modulation studies, safety profiling, and human tissue validation.
Key Findings
- Single-cell RNA-seq in CLP sepsis revealed metabolically impaired subpopulations among endothelial cells, fibroblasts, and macrophages with dysfunctional mitochondrial respiration.
- Drp1 interacts with Filamin and Kinesin to coordinate TNT biogenesis and extension, enabling long-range mitochondrial trafficking.
- Cardiac-specific Drp1 knockout abrogated TNT-mediated mitochondrial exchange, halted metabolic deterioration, and reversed cellular reprogramming in sepsis.
Methodological Strengths
- Integration of in vivo CLP model, single-cell transcriptomics, and genetic knockout for causal inference.
- Mechanistic dissection of protein–protein interactions (Drp1–Filamin–Kinesin) linked to functional organelle transfer.
Limitations
- Findings are limited to murine models; no human myocardial validation presented.
- Lack of pharmacologic modulation data to complement genetic knockout and address translatability and safety.
Future Directions: Evaluate pharmacologic Drp1/TNT modulators, validate TNT-mediated mitochondrial transfer in human cardiac tissues, and develop imaging biomarkers to monitor TNT networks in vivo.
Sepsis-induced cardiac dysfunction arises from complex intercellular communication networks that extend beyond direct cardiomyocyte damage, yet the nanoscale mechanisms governing these interactions remain poorly understood. Here, we identify tunneling nanotubes (TNTs) as dynamic biological nanostructures facilitating intercellular mitochondrial transfer, revealing their critical role in septic cardiac remodeling. Using a murine cecal ligation and puncture (CLP) model and single-cell RNA sequencing, we demonstrate that sepsis reprograms cardiac endothelial cells, fibroblasts, and macrophages, generating metabolically impaired subpopulations with dysfunctional mitochondrial respiration. We uncover a Drp1-driven cytoskeletal remodeling process that orchestrates TNT biogenesis, wherein Drp1 interacts with Filamin and Kinesin to regulate TNT formation and extension, enabling long-range organelle trafficking. Cardiac-specific Drp1 knockout disrupts TNT-mediated mitochondrial exchange, halting metabolic deterioration and reversing cellular reprogramming. These findings establish Drp1-mediated TNT networks as nanoscale conduits of organelle communication, offering insights into biological nanotube engineering, cellular-scale nanotechnology, and potential therapeutic interventions for mitochondrial dysfunction in sepsis.
3. [Safety and effectiveness of the early-onset sepsis calculator to reduce antibiotic exposure in at-risk newborns: a cluster-randomised controlled trial].
In a multicenter cluster-RCT of 1,830 newborns ≥34 weeks with EOS risk factors, the EOS calculator halved predefined harm criteria and reduced empiric antibiotic initiation from 26.6% to 7.2% within 24 hours postpartum. Implementation appears safe and substantially improves neonatal antibiotic stewardship.
Impact: Directly informs practice with high-quality randomized evidence showing safe, large reductions in empiric antibiotics for at-risk newborns.
Clinical Implications: Hospitals can implement the EOS calculator to reduce unnecessary antibiotic exposure in ≥34-week neonates with risk factors while maintaining safety, supporting antimicrobial stewardship and potentially lowering downstream adverse effects.
Key Findings
- Cluster-RCT across 10 hospitals enrolled 1,830 newborns ≥34 weeks with ≥1 EOS risk factor.
- Predefined harm criteria occurred less often with EOS calculator vs categorical guideline (7.0% vs 14.6%; RR 0.48, 95% CI 0.36–0.63).
- Empiric antibiotic initiation within 24 h postpartum was reduced from 26.6% to 7.2% (absolute risk reduction 19.0%; 95% CI 11.3–26.7).
Methodological Strengths
- Multicenter cluster-randomized design with prespecified non-inferiority harm endpoints and superiority analysis for antibiotic reduction.
- Large sample size (n=1,830) enabling precise estimates and pragmatic implementation assessment.
Limitations
- Open-label cluster design may introduce performance bias; results derive from Dutch hospitals which may limit generalizability.
- Long-term outcomes (resistance patterns, microbiome, neurodevelopment) were not reported.
Future Directions: External validation in diverse health systems, integration with EHR workflows, and evaluation of long-term outcomes including antimicrobial resistance and microbiome effects.
OBJECTIVE: Assessing the safety and effectiveness of the early-onset sepsis (EOS) calculator compared with the categorical guideline in reducing empiric antibiotic treatment in newborns with suspected EOS. DESIGN: Open-label, cluster-randomised controlled trial in 10 Dutch hospitals, randomised 1:1 to the EOS calculator or the categorical guideline. METHOD: 1830 newborns (gestational age ≥34 weeks, ≥1 EOS risk factor) were included. Non-inferiority was assessed using four predefined harm criteria (respiratory support, circulatory support, culture-proven EOS, referral to tertiary hospital). Superiority was assessed as reduction of empiric antibiotics <24 hours postpartum. RESULTS: At least one harm criterion was present in 7.0% (64/915) of the EOS calculator arm, compared to 14.6% (134/915) in the categorical guideline arm (relative risk 0.48; 95% CI 0.36-0.63). Antibiotics were started in 7.2% (66/915) versus 26.6% (243/915), respectively (absolute risk reduction: 19.0%, 95% CI 11.3-26.7). CONCLUSION: EOS calculator implementation safely reduces empiric antibiotic use in newborns.